Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 755 full-time employees. The company went IPO on 2013-10-30. The firm enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The firm offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). The company has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

Industry: Services-Medical Laboratories Peers: CHINOOK THERAPEUTICS, INC. Akero Therapeutics, Inc. Celldex Therapeutics Inc Catalyst Pharmaceuticals Inc Deciphera Pharmaceuticals, Inc. DYNAVAX TECHNOLOGIES CORP Ligand Pharmaceuticals Inc Syndax Pharmaceuticals Inc SpringWorks Therapeutics, Inc.